Seizert Capital Partners’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$5.27M Sell
37,822
-1,044
-3% -$146K 0.24% 67
2025
Q4
$4.77M Sell
38,866
-602
-2% -$73.2K 0.2% 70
2025
Q3
$4.38M Sell
39,468
-7,791
-16% -$886K 0.19% 78
2025
Q2
$5.24M Hold
47,259
0.23% 71
2025
Q1
$5.3M Buy
47,259
+58
+0.1% +$5.99K 0.24% 67
2024
Q4
$4.36M Sell
47,201
-2,063
-4% -$186K 0.2% 87
2024
Q3
$4.13M Buy
49,264
+119
+0.2% +$9.08K 0.19% 95
2024
Q2
$3.37M Sell
49,145
-7,255
-13% -$484K 0.17% 90
2024
Q1
$4.13M Sell
56,400
-2,205
-4% -$170K 0.19% 80
2023
Q4
$4.75M Sell
58,605
-26,178
-31% -$2.04M 0.24% 74
2023
Q3
$6.35M Buy
84,783
+229
+0.3% +$17.6K 0.34% 57
2023
Q2
$6.52M Sell
84,554
-8,704
-9% -$694K 0.35% 59
2023
Q1
$7.74M Sell
93,258
-26,738
-22% -$2.21M 0.43% 55
2022
Q4
$10.3M Sell
119,996
-11,797
-9% -$934K 0.55% 49
2022
Q3
$8.13M Sell
131,793
-565
-0.4% -$35.6K 0.46% 56
2022
Q2
$8.18M Buy
132,358
+6,845
+5% +$424K 0.43% 55
2022
Q1
$7.46M Buy
125,513
+574
+0.5% +$36.7K 0.34% 64
2021
Q4
$9.07M Buy
124,939
+997
+0.8% +$68.7K 0.41% 58
2021
Q3
$8.66M Buy
123,942
+3
+0% +$211 0.4% 59
2021
Q2
$8.53M Buy
123,939
+3,639
+3% +$243K 0.41% 60
2021
Q1
$7.78M Buy
+120,300
New +$7.76M 0.41% 64
2020
Q4
Sell
-10,184
Closed -$644K 195
2020
Q3
$644K Hold
10,184
0.04% 135
2020
Q2
$784K Sell
10,184
-260,098
-96% -$19.9M 0.05% 123
2020
Q1
$20.2M Sell
270,282
-343,053
-56% -$23.7M 1.49% 28
2019
Q4
$39.9M Buy
613,335
+28,151
+5% +$1.83M 1.98% 17
2019
Q3
$37.1M Sell
585,184
-19,122
-3% -$1.25M 1.87% 19
2019
Q2
$40.8M Sell
604,306
-43,877
-7% -$2.89M 2.01% 19
2019
Q1
$42.1M Buy
648,183
+64,231
+11% +$4.27M 1.89% 19
2018
Q4
$36.5M Sell
583,952
-67,389
-10% -$4.71M 1.65% 19
2018
Q3
$50.3M Buy
651,341
+16,972
+3% +$1.28M 1.85% 16
2018
Q2
$47.8M Hold
634,369
1.74% 16
2018
Q1
$47.8M Buy
634,369
+724
+0.1% +$57.6K 1.74% 16
2017
Q4
$45.4M Buy
633,645
+40,656
+7% +$3.09M 1.63% 22
2017
Q3
$48M Sell
592,989
-38,280
-6% -$2.93M 1.76% 18
2017
Q2
$44.7M Sell
631,269
-1,305
-0.2% -$86.8K 1.62% 24
2017
Q1
$43M Buy
632,574
+27,547
+5% +$1.94M 1.53% 25
2016
Q4
$43.3M Buy
605,027
+7,899
+1% +$587K 1.54% 21
2016
Q3
$47.2M Sell
597,128
-13,737
-2% -$1.12M 1.75% 16
2016
Q2
$51M Sell
610,865
-56,487
-8% -$5.01M 1.93% 11
2016
Q1
$61.3M Buy
667,352
+151,118
+29% +$13.6M 2.09% 6
2015
Q4
$52.2M Buy
516,234
+10,647
+2% +$1.11M 1.63% 23
2015
Q3
$49.6M Buy
505,587
+63,722
+14% +$7.08M 1.5% 26
2015
Q2
$51.7M Buy
441,865
+18,434
+4% +$2.01M 1.32% 38
2015
Q1
$41.6M Sell
423,431
-30,080
-7% -$3.05M 1.05% 45
2014
Q4
$42.7M Buy
453,511
+191,752
+73% +$19.8M 0.9% 52
2014
Q3
$27.9M Buy
261,759
+1,602
+0.6% +$157K 0.56% 65
2014
Q2
$21.6M Buy
260,157
+13,495
+5% +$1.05M 0.43% 67
2014
Q1
$17.5M Sell
246,662
-3,426
-1% -$269K 0.41% 67
2013
Q4
$18.8M Sell
250,088
-66,510
-21% -$4.63M 0.44% 64
2013
Q3
$19.9M Sell
316,598
-76,950
-20% -$4.6M 0.54% 60
2013
Q2
$20.2M Buy
+393,548
New +$20.5M 0.55% 58

Other funds holding GILD

Seizert Capital Partners's GILD Position: Q1 2026 in Review

Seizert Capital Partners reduced its Gilead Sciences (GILD) stake by 2.7% in Q1 2026, selling an estimated $146K and leaving 37,822 shares worth $5.27M. The position accounts for 0.24% of the portfolio, ranked #67.

Seizert Capital Partners first reported a position in GILD in Q2 2013 and has held it in 51 quarters since. The position peaked at $61.3M in Q1 2016. 2,311 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Seizert Capital Partners held 37,822 shares of Gilead Sciences worth $5.27M as of Q1 2026.
  • Seizert Capital Partners sold 1,044 Gilead Sciences shares in Q1 2026, an estimated $146K.
  • Gilead Sciences made up 0.24% of Seizert Capital Partners's portfolio in Q1 2026, its #67 holding.
  • Seizert Capital Partners first reported a position in Gilead Sciences in Q2 2013 and has held it in 51 quarters since.
  • Seizert Capital Partners's Gilead Sciences position peaked at $61.3M in Q1 2016.
  • 2,311 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Seizert Capital Partners's 13F filing for Q1 2026, filed 7 May 2026.